HeartSciences PE Ratio 2022-2026 | HSCS
Current and historical p/e ratio for HeartSciences (HSCS) from 2022 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. HeartSciences PE ratio as of May 19, 2026 is 0.00.
| HeartSciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-05-20 | 1.93 | 0.00 | |
| 2026-01-31 | 3.23 | $-4.92 | 0.00 |
| 2025-10-31 | 3.05 | $-6.86 | 0.00 |
| 2025-07-31 | 3.12 | $-8.28 | 0.00 |
| 2025-04-30 | 3.51 | $-9.34 | 0.00 |
| 2025-01-31 | 3.23 | $5.94 | 0.54 |
| 2024-10-31 | 2.94 | $5.50 | 0.53 |
| 2024-07-31 | 3.85 | $-8.15 | 0.00 |
| 2024-04-30 | 9.20 | $-18.74 | 0.00 |
| 2024-01-31 | 15.00 | $-46.16 | 0.00 |
| 2023-10-31 | 24.90 | $-59.15 | 0.00 |
| 2023-07-31 | 87.20 | $-65.23 | 0.00 |
| 2023-04-30 | 88.80 | $-80.00 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.007B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $24.733B | 27.19 |
| Tempus AI (TEM) | United States | $7.677B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $4.429B | 38.86 |
| Doximity (DOCS) | United States | $3.888B | 16.84 |
| IRhythm Holdings (IRTC) | United States | $3.724B | 0.00 |
| 10x Genomics (TXG) | United States | $2.973B | 0.00 |
| Privia Health (PRVA) | United States | $2.810B | 131.59 |
| Hinge Health (HNGE) | United States | $2.789B | 0.00 |
| Heartflow (HTFL) | United States | $2.311B | 0.00 |
| Omnicell (OMCL) | United States | $1.564B | 43.00 |
| Inspire Medical Systems (INSP) | United States | $1.555B | 20.94 |
| Enovis (ENOV) | United States | $1.405B | 7.40 |
| Butterfly Network (BFLY) | United States | $1.047B | 0.00 |
| Azenta (AZTA) | United States | $1.023B | 41.13 |
| Clover Health Investments (CLOV) | United States | $1.013B | 0.00 |
| Talkspace (TALK) | United States | $0.864B | 103.40 |
| Schrodinger (SDGR) | United States | $0.839B | 0.00 |
| Phreesia (PHR) | United States | $0.490B | 50.38 |
| Fulgent Genetics (FLGT) | United States | $0.429B | 0.00 |
| Standard BioTools (LAB) | United States | $0.345B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.322B | 0.00 |
| CapsoVision (CV) | United States | $0.311B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.279B | 0.00 |
| Claritev (CTEV) | United States | $0.269B | 0.00 |
| TruBridge (TBRG) | United States | $0.268B | 8.60 |
| Evolent Health (EVH) | United States | $0.260B | 0.00 |
| Carlsmed (CARL) | United States | $0.239B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.196B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.189B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 8.18 |
| Nyxoah SA (NYXH) | Belgium | $0.111B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.102B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| American Well (AMWL) | United States | $0.086B | 0.00 |
| Outset Medical (OM) | United States | $0.077B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.058B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.034B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.018B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.009B | 0.00 |
| Zhongchao (ZCMD) | China | $0.008B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |